ASP3772 utilizes the Multiple Antigen Presenting System (MAPS) platform which is Affinivax’s proprietary, next-generation vaccine technology. MAPS uniquely presents key epitopes of the desired antigens (polysaccharides and/or proteins) to induce a robust and broad immune response against challenging diseases.
ASP3772 is a vaccine candidate that offers the potential to provide broader protection against pneumococcal disease.
ASP3772 administered as a singular intramuscular injection
February 13, 2019: the first subject was dosed with ASP3772, a novel MAPS vaccine targeting Streptococcus pneumoniae (pneumococcus).
This followed the successful submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in December 2018.
Clinical Trial NCT03803202: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine (Recruiting)
- The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1.
- Stage 2 will evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator PCV13 in elderly 65 to 85 years of age.
- In addition, Stage 2 will evaluate the immunogenicity of 3 different dose levels of ASP3772 relative to the response seen following administration of Pneumovax® 23 (PPSV23) for the serotypes not included in PCV13.